| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
25,161 |
22,256 |
$2.50M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
23,625 |
20,116 |
$1.62M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
8,690 |
7,578 |
$434K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
8,888 |
8,436 |
$407K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,201 |
3,124 |
$319K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,317 |
2,869 |
$300K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,346 |
2,195 |
$256K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,277 |
2,152 |
$228K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,907 |
4,682 |
$139K |
| 90461 |
|
3,552 |
3,427 |
$123K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
8,287 |
7,688 |
$119K |
| 99215 |
Prolong outpt/office vis |
536 |
490 |
$76K |
| 97802 |
|
3,076 |
2,964 |
$76K |
| 99051 |
|
4,264 |
4,005 |
$50K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,841 |
1,725 |
$41K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
980 |
947 |
$38K |
| G9153 |
Mapcp demonstration - physician incentive pool |
826 |
783 |
$33K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
4,646 |
4,506 |
$33K |
| 99381 |
|
300 |
246 |
$31K |
| 97803 |
|
1,583 |
1,385 |
$29K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
588 |
548 |
$29K |
| 96127 |
|
3,921 |
3,765 |
$27K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,040 |
1,859 |
$24K |
| 87807 |
|
1,359 |
1,264 |
$16K |
| 81002 |
|
4,086 |
3,783 |
$12K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
77 |
77 |
$11K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
54 |
54 |
$8K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,890 |
1,483 |
$7K |
| 81025 |
|
637 |
603 |
$4K |
| 99401 |
|
142 |
140 |
$4K |
| 99383 |
|
28 |
26 |
$3K |
| 99384 |
|
14 |
14 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
598 |
426 |
$1K |
| 69210 |
|
43 |
42 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13 |
13 |
$1K |
| G9762 |
Patient had at least two hpv vaccines (with at least 146 days between the two) or three hpv vaccines on or between the patient's 9th and 13th birthdays |
13 |
13 |
$450.00 |
| 80305 |
|
15 |
13 |
$137.62 |
| 94760 |
|
150 |
119 |
$69.37 |
| 90651 |
|
913 |
879 |
$0.00 |
| 90696 |
|
247 |
239 |
$0.00 |
| 90744 |
|
364 |
353 |
$0.00 |
| 90680 |
|
161 |
157 |
$0.00 |
| 90698 |
|
504 |
492 |
$0.00 |
| 90647 |
|
659 |
645 |
$0.00 |
| 90723 |
|
168 |
161 |
$0.00 |
| 90686 |
|
140 |
137 |
$0.00 |
| 90697 |
|
81 |
80 |
$0.00 |
| 99000 |
|
44 |
43 |
$0.00 |
| 90670 |
|
2,077 |
2,039 |
$0.00 |
| 90734 |
|
925 |
895 |
$0.00 |
| 90715 |
|
637 |
615 |
$0.00 |
| 90700 |
|
442 |
439 |
$0.00 |
| 90633 |
|
1,994 |
1,943 |
$0.00 |
| 90681 |
|
392 |
382 |
$0.00 |
| 90710 |
|
1,084 |
1,055 |
$0.00 |
| 90649 |
|
423 |
400 |
$0.00 |
| 90658 |
|
560 |
546 |
$0.00 |
| 90713 |
|
12 |
12 |
$0.00 |
| 90672 |
|
19 |
19 |
$0.00 |